Uroplasty to Highlight Urgent PC System at American Urological Association 2008 Annu...( MINNEAPOLIS May 12 /- Uroplasty I...),Health

MINNEAPOLIS, May 12 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunction, announced today that Kenneth M. Peters, M.D., chair of the Department of Urology at Beaumont Hospital in Royal Oak, Michigan, will present preliminary data from the ongoing OrBIT (Overactive Bladder Innovative Therapy) study of the Urgent(R) PC Neuromodulation System at the American Urological Association's annual meeting. Uroplasty's Urgent PC system and Macroplastique(R) will also be featured in seven presentations by leading urologists at Uroplasty's Booth # 3729. The AUA 2008 Annual Meeting will be held from May 17 to May 22 in Orlando, Florida.

"The annual AUA meeting has always been one of the best opportunities for interacting with our customers, and we are excited to host a prestigious line-up of leading urologists who will address the ease-of-use, safety and efficacy of our Urgent PC system for the treatment of urinary frequency, urinary urgency and urge incontinence, symptoms often associated with overactive bladder, and Macroplastique for the treatment of adult female stress urinary incontinence," said Dave Kaysen, President and Chief Executive Officer of Uroplasty, Inc. "We also eagerly anticipate Dr. Peters' presentation of the OrBIT trial. As the clinical evidence supporting Urgent PC continues to expand, we fully expect that even greater numbers of patients and physicians alike will seek out the Urgent PC technology's patient-friendly, highly effective solution to a large and persistent quality of life issue."

Poster Presentation

In a moderated poster presentation, "A Randomized Multi-Center Study Comparing Percutaneous Tibial Nerve Stimulation (PTNS) with Pharmaceutical Therapy for the Treatment of Overactive Bladder," Kenneth M. Peters, M.D., will present preliminary results from the ongoing OrBIT clinical study
'/>"/>